MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma - Seite 2
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a
leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody
drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
About Lanthio Pharma:
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide technology to the discovery of novel peptide therapeutics with longer half-life and high
receptor selectivity.
Lanthio Pharma is building a pipeline of therapeutic lanthipeptide drugs against diseases of high medical interest, including fibrosis, cardiovascular diseases, multiple sclerosis and
cancer.
Constrained peptides like lanthipeptides are an emerging compound class which offers the potential to address many types of target and disease categories, currently beyond reach for therapeutic
proteins or small molecules. The technology of Lanthio Pharma includes a proprietary bacterial display library capability, which allows construction of focused or randomized libraries of
lanthipeptides that can be screened against disease targets of interest. MorphoSys AG has obtained the rights to commercialize Lanthio's technology.
Lanthio Pharma is funded by Inkef Capital, BioGeneration Ventures, MorphoSys and RUG Holding.
Lesen Sie auch
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.